DGAP-Adhoc: M1 Kliniken AG successfully completes capital increase
05.10.2017 (www.4investors.de) -
DGAP-Ad-hoc: M1 Kliniken AG / Key word(s): Capital Increase
M1 Kliniken AG successfully completes capital increase
05-Oct-2017 / 08:51 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
M1 Kliniken AG successfully completes capital increase.
Berlin, October 5, 2017 - M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) has successfully completed the capital increase in accordance with the resolutions passed yesterday and today. The capital increase was oversubscribed several times.
The Company increased its share capital by EUR 1,500,000.00 to EUR 16,500,000.00 by issuing a total of 1,500,000 no-par value bearer shares in exchange for cash contributions, to the exclusion of shareholders' statutory subscription rights, making partial use of authorized capital 2015. The new shares are entitled to dividends as of January 1,2017.
The capital increase was carried out to the maximum possible extent. The placement price determined by the Company's Management Board with the approval of the Supervisory Board was EUR 11.00 per share. Due to the high demand, the new shares were sold to institutional investors as part of an accelerated private placement process. Subject to registration of the capital increase in the commercial register, M1 Klinken AG will receive gross proceeds of approximately EUR 16,500,000.00 from the capital increase.
The new shares are to be included in the open market trading of the Frankfurt Stock Exchange (Basic Standard) without a prospectus. Delivery and settlement of the new shares is expected to take place on October 11, 2017.
The capital increase was accompanied by B. Metzler seel. Sohn & Co. KGaA.
M1 Kliniken AG intends to use the proceeds from the capital increase to finance further growth investments and, in particular, to finance the construction of additional M1 Med-Beauty locations.
M1 Kliniken AG
The Board of Directors
The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.
Company: M1 Kliniken AG
Grünauer Str. 1
Phone: +49 (0)30-887086225
Fax: +49 (0)30-887086228
Stock exchanges: Frankfurt, Stuttgart, Düsseldorf, Xetra
Patrick Brenske, Management Board
05-Oct-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
M1 Kliniken AG
Grünauer Straße 5
+49 (0)30 / 88 70 862-25
+49 (0)30 / 88 70 862-28
Regulated Unofficial Market in Dusseldorf, Stuttgart; Open Market (Basic Board) in Frankfurt
End of Announcement
DGAP News Service
616077 05-Oct-2017 CET/CEST
HanseYachts: „Unser Verkaufsapparat läuft inzwischen wie eine geölte Maschine“ - Exklusiv-Interview
NOXXON Pharma: DEWB-Beteiligung steht vor wichtigen Meilensteinen - Exklusiv-Interview